SCHEMBL23684239

SCHEMBL23684239

CC(C)(C)OC(=O)c1cccc(C=C2CCOCC2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 1/20 0.41
▸ CASR P41180 1/20 0.38
▸ SRD5A1 P18405 2/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ STAT3 P40763 1/20 0.35
▸ P4HB P07237 3/20 0.34
▸ GRIN2D O15399 1/20 0.34
▸ GRIN3B O60391 1/20 0.34
▸ GRIN1 Q05586 1/20 0.34
▸ GRIN2A Q12879 1/20 0.34
▸ GRIN2B Q13224 1/20 0.34
▸ GRIN2C Q14957 1/20 0.34
▸ GRIN3A Q8TCU5 1/20 0.34
▸ GABRA1 P14867 1/20 0.34
▸ GABRG2 P18507 1/20 0.34
▸ GABRB3 P28472 1/20 0.34
▸ GABRA3 P34903 1/20 0.34
▸ GABRA2 P47869 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30260159 1.00 SLC7A5 (0.41) SLC7A5CASRSRD5A1TDP1STAT3
SCHEMBL23684304 0.79 UNG (0.53) SRD5A1TDP1P4HBLMNA
SCHEMBL895414 0.76 UNG (0.56) SLC7A5TDP1STAT3P4HBGRIN2D
SCHEMBL6392515 0.75 GRM5 (0.45) SRD5A1TDP1P4HBGRIN2DGRIN3B
SCHEMBL31487534 0.75 SLC7A5 (0.48) SLC7A5TDP1STAT3P4HBGRIN2D
SCHEMBL2948778 0.75 TDP1 (0.53) TDP1P4HBGRIN2DGRIN3BGRIN1
SCHEMBL15496946 0.75 SLC7A5 (0.48) SLC7A5TDP1STAT3P4HBGRIN2D
SCHEMBL110296 0.73 SLC7A5 (0.58) SLC7A5SRD5A1TDP1STAT3GABRA1
SCHEMBL5732625 0.73 LMNA (0.38) SRD5A1TDP1GRIN2DGRIN3BGRIN1
SCHEMBL20299500 0.73 TUBB4A (0.49) SLC7A5TDP1L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11986471-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2024-05-21 — — US disclosed
US-20230060499-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-20230060499-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-11077101-B1 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2021-08-03 — — US disclosed
US-11077101-B1 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2021-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11986471-B2 Compounds and methods of use XDH, F12, LPXN SLC7A5 2181/4885CASR 2994/4885SRD5A1 320/4885
US-11077101-B1 Compounds and methods of use XDH, F12, LPXN SLC7A5 2181/4885CASR 2994/4885SRD5A1 320/4885
US-20230060499-A1 COMPOUNDS AND METHODS OF USE XDH, F12, LPXN SLC7A5 2181/4885CASR 2994/4885SRD5A1 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback